"glp 1s" explained: this article covers what GLP-1 is as a hormone, how receptor agonists work, which medications belong to the class, FDA-approved indications, shared boxed-warning safety profile, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Ozempic weight-loss outcomes are widely discussed and often misrepresented in before-and-after content. This article covers what published Phase 3 trials (STEP, SURMOUNT, SCALE) report as mean outcomes, typical timeline patterns, why individual outcomes vary, and why photos are not reliable guides to expectation-setting.

Zepbound (tirzepatide) is the first FDA-approved medication for obstructive sleep apnea in adults with obesity — approved December 2024 based on the SURMOUNT-OSA trial. This article covers the weight-mediated mechanism, who may benefit, class-wide safety warnings, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes. This article covers mechanism, evidence base, FDA labeling, safety, and the upstream genetic variables — including TCF7L2, GLP1R, and FTO — that shape every type 2 diabetes decision.

Zepbound is Eli Lilly's tirzepatide brand for chronic weight management (2023) and obstructive sleep apnea (2024) — it is NOT FDA-approved for type 2 diabetes. Mounjaro is the same molecule separately approved for diabetes. This article explains the brand distinction, April 2026 cost, and the FTO, GLP1R, TCF7L2, and MC4R genetic architecture.

Ozempic (semaglutide) is FDA-approved for type 2 diabetes. This article covers mechanism, evidence base, FDA labeling, safety, and the upstream genetic variables — including TCF7L2, GLP1R, and FTO — that shape every type 2 diabetes decision.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — covering 8 peptide pathways, 11 SNPs, and 9 genes including FTO, MC4R, PPARG, TCF7L2, and GIPR. This comprehensive guide explains what each insight cluster covers, which peptide pathways are analyzed, and why genetic specificity is the missing variable in most weight management decisions.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including the pathways most relevant to GLP-1 receptor signaling. This article explains what the research shows about genetics and semaglutide response, why MTHFR methylation status matters in the broader metabolic picture, and how genetic testing can help inform a smarter weight management approach.

The PlexusDx Precision Peptide Genetic Test analyzes 34 weight management genetic insights — including GLP-1 receptor signaling and GIPR response pathways. This article explains how genes like FTO, MC4R, and PPARG influence appetite, fat metabolism, and weight regulation, and why your DNA may be the most underused variable in any weight management decision.

A Diabetes Care analysis estimates tirzepatide may reduce MACE risk by up to 28% and all-cause mortality by 39% compared to theoretical placebo — a figure the SURPASS-CVOT trial design couldn't directly show. Here's what the imputed placebo data reveals, and why GLP-1 receptor pathway genetics matter before any weight management decision.